Previous studies have demonstrated that mutant KRAS can reprogram metabolism in PDAC to facilitate tumor adaptation to a harsh microenvironment.[12, 19, 48] However, other molecular regulators contributing to this metabolic remodeling remain poorly characterized. The gene discussed is KRAS; the disease is neoplasm.